China Shineway Pharmaceutical Group Limited (CSWYF) Stock Price & Analysis
China Shineway Pharmaceutical Group Limited (CSWYF) — price $1.00 (0.00%), as of the Nov 19, 2026 trading session; market cap $758M.
Educational signal · not a buy or sell recommendation · How to read this
China Shineway Pharmaceutical Group Limited · CSWYF
China Shineway Pharmaceutical Group Limited focuses on the research, development, manufacture, and trade of Chinese medicines. The company offers modern Chinese medicines and TCM Formula Granules across various therapeutic areas.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.00 | |
| Change on the day | 0.00% | |
| 52-week range | $0.9253 – $1.00 | |
| Market capitalisation | $758M | |
| Price / earnings (trailing) | 6.45 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for China Shineway Pharmaceutical Group (CSWYF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is China Shineway Pharmaceutical Group (CSWYF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. China Shineway Pharmaceutical Group Limited (CSWYF) is the company analyzed here. It employs 2,822 people and is led by Zhenjiang Li. In Q4 FY2024 it reported revenue of CN¥3.49B and net income of CN¥754M. The market values it at $758M.
What do the latest results show for China Shineway Pharmaceutical Group (CSWYF)?
Short answer · as of
The most recent reported quarter, Q4 FY2024, carried revenue of CN¥3.49B.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2024 | CN¥3.49B | CN¥754M | CN¥1.00 (diluted) |
| Q2 FY2024 | CN¥2.09B | CN¥626M | CN¥0.83 (diluted) |
What are the financial strengths and risks for China Shineway Pharmaceutical Group (CSWYF)?
Short answer · as of
The distress and quality screens read Altman Z 4.19 · Piotroski F 7. Trailing ratios: ROE 9.8% · ROA 7.6% · current ratio 4.32 · earnings yield 16.2% · free-cash-flow yield 18.1%.
What should you watch next at China Shineway Pharmaceutical Group (CSWYF)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $2.63B · EPS 1.02 · 2 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q4 FY2024) was filed Dec 31, 2024 — 14 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $2.63B
- EPS estimate
- $1.02
Measured against a quoted price of $1.00 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CSWYF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CSWYF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About CSWYF
These answers are editorial: 1 of these 8 answers is drawn from the CSWYF research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is CSWYF a good stock to buy?
Stock Expert AI does not rate CSWYF buy, sell or hold. China Shineway Pharmaceutical Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CSWYF stock price today?
The last price recorded for China Shineway Pharmaceutical Group Limited (CSWYF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for CSWYF?
China Shineway Pharmaceutical Group Limited faces several risks, including regulatory changes in the pharmaceutical industry, competition from other drug manufacturers, and pricing pressures. As an OTC-listed company, CSWYF also faces risks related to liquidity and transparency. Dependence on the Chinese market exposes the company to economic and political risks. Investors should carefully consider these factors before investing in CSWYF.
What are the key factors to evaluate for CSWYF?
Evaluate CSWYF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This can lead to increased market share and higher profit margins. Not financial advice.
How frequently does CSWYF data refresh on this page?
CSWYF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CSWYF's recent stock price performance?
China Shineway Pharmaceutical Group Limited (CSWYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese medicine market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSWYF overvalued or undervalued right now?
The trailing P/E of China Shineway Pharmaceutical Group Limited (CSWYF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CSWYF before investing?
Before investing in China Shineway Pharmaceutical Group Limited (CSWYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP) and 8 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com